Abstract Introduction Hyponatremia is the most common electrolyte imbalance caused by serum sodium level of less than 135 mmol/L, prevailing 15 and 30% among hospitalised patients. Methods PRISMA guidelines were followed for this study. Pubmed was searched with the search term: (hyponatremia) AND (treatment OR control OR management [MeSH]) AND (elderly [MeSH]) with filters, timeline: 2000 to 21/07/2023, free full text articles and human species. Data extraction was done using Covidence app and depicted in PRISMA Flow diagram. Quality assessment was done by Cochrane Risk of Bias version 1. Odd’s ratio with 95% confidence interval was calculated for dichotomous outcomes. Mantel–Haenszel statistical method along with random effects model was used. Cochrane Q test was employed and I2 index was computed. Forest and Funnel plots were plotted. The analysis was done by Cochrane Review Manager. Results Out of 3222 results, 9 studies were included with total 980 patients. Eight were of vaptans and 1 of empagliflozin. Three studies had low risk of bias and were included in meta-analysis. Mean age and BMI were 70.55(SD = 14.5) years and 24.73(SD = 3.95) kg/m2 respectively. Most frequently occuring aetiology, comorbidity and symptom were congestive heart failure, hypertension and fatigue/malaise respectively. Mean baseline serum sodium was 124.89 mmol/L and mean rise was 9.142 mmol/L. Meta-analysis showed that placebo was significantly associated with achieving normonatremia as compared to treatment group (OR = 2.5, 95%CI:1.54,4.04, p = 0.0002,I2 = 0%). The most frequent reported side effects were nausea, dry mouth, pyrexia and thirst. Side effects both mild/moderate (OR = 1.12, 95%CI:0.69,1.81, p = 0.65, I2 = 0%) and serious (OR = 1.51, 95%CI: 0.77,2.98, p = 0.23, I2 = 0%) showed no difference between treatment and placebo groups. Treatment was not associated with rapid risk of overcorrection (OR = 1.65, 95% CI:0.57,4.81, p = 0.36, I2 = 0%). None showed osmotic demyelination syndrome. Conclusion We conclude that vaptans and Empagliflozin, although safe, show limited efficacy in hyponatremia treatment. Reference 1. Zhang X, Li XY. Eur Geriatr Med. 2020;11(4):685–692.
Read full abstract